A Dubai longevity clinic urged annual tumor marker tests for routine health checks, but leading oncologists warn these markers are not suitable for population‑wide cancer screening. Their true value lies in monitoring diagnosed cancers, not in early detection for healthy individuals.

Key Takeaways

  • Tumor markers are not appropriate for routine cancer screening in healthy adults.
  • They are primarily useful for monitoring known cancers, treatment response, and recurrence.
  • Indiscriminate use can lead to false‑positives, unnecessary procedures, and false reassurance.

A Dubai‑based longevity clinic recently recommended that annual tumor‑marker panels—CEA, CA‑125, AFP, CA 19‑9, and PSA—be added to standard health‑check packages to catch cancer early. Oncologists such as Dr. Saneya Pandrowala, Consultant GI & HPB Oncosurgery at KIMS Hospitals, Thane, caution that international guidelines do not endorse these blood tests as a general screening tool for asymptomatic adults.

Guidelines and the Limits of Screening

World Health Organization (WHO) and major cancer societies emphasize that tumor markers have not demonstrated a mortality benefit when used for population‑wide screening. Effective screening programs are targeted—mammography for breast cancer, Pap smears for cervical cancer, and colonoscopy for colorectal cancer—based on age, risk factors, and disease prevalence. Tumor markers lack the specificity and sensitivity required for such broad application.

Clinical Role of Tumor Markers

These biomarkers become valuable after a cancer diagnosis. They help clinicians assess treatment efficacy, detect recurrence, and gauge disease progression. For instance, CEA often rises in colorectal cancer, CA‑125 is linked to ovarian malignancies, AFP may increase in liver cancer and certain germ‑cell tumors, CA 19‑9 is associated with pancreatic and biliary cancers, and PSA serves as a marker for prostate pathology.

Non‑cancer Elevations and Interpretation Pitfalls

Elevated levels are not exclusive to malignancy. Infections, inflammatory conditions, liver disease, pancreatitis, endometriosis, and even smoking (for CEA) can raise these markers. Conversely, many early‑stage cancers present with normal marker levels. A false‑positive result can trigger anxiety, costly imaging, and invasive procedures, while a false‑negative result may provide false reassurance and delay definitive diagnosis.

When Is Testing Appropriate?

Dr. Pandrowala advises that tumor‑marker testing should be ordered based on clinical judgment—not as part of a generic wellness package. Indications include patients with a known cancer, or when symptoms, physical findings, or imaging raise suspicion for a specific malignancy. High‑risk groups—individuals with chronic liver disease, hereditary cancer syndromes, or a strong family history—may benefit from selective marker panels as part of a broader surveillance strategy, always interpreted alongside imaging and other investigations.

Bottom Line

While tumor‑marker assays play a crucial role in cancer management, they are not a substitute for evidence‑based screening protocols or an annual check‑up for healthy adults. Physicians must emphasize proven screening modalities and reserve tumor‑marker testing for situations where it adds clear diagnostic value.